CapsoVision, Inc. (CV)

CapsoVision went public on July 2, 2025, at $5.00 per share. In November 2025, it submitted a Breakthrough Device Designation application to the FDA for its CapsoCam UGI system and reported a 19% revenue increase. In December 2025, the stock reached an all-time high of $14.42 and submitted a 510(k) application to the FDA for its AI-assisted module. In March 2026, the company completed a $14 million private placement and reported a 13% increase in fourth-quarter revenue, but operating expenses surged, leading to a negative earnings outlook and an 8.95% stock decline. Benchmark cut its price target to $10. In April 2026, CapsoVision filed a Form S-1. By May 8, 2026, the stock price was $7.12.

The provided information does not contain specific details regarding the demand seasonality for CapsoVision, Inc.'s products and services. However, the broader capsule endoscopy market is experiencing robust growth driven by increasing incidences of gastrointestinal disorders, a rising demand for rapid and non-invasive diagnostic tools, and technological advancements such as high-resolution imaging and AI integration.

CapsoVision, Inc. is a medical technology company specializing in advanced imaging and AI technologies for endoscopy solutions. The company operates in the Healthcare sector, focusing on Medical Devices and Diagnostic Equipment. Its core business revolves around capsule endoscopy systems for internal imaging of the GI system. Major products include CapsoCam Plus®, CapsoCloud™, CapsoView™, CapsoAccess™, CapsoRetrieve™, CapsoCam Colon™, and CapsoColon 3D. CapsoVision also offers capsule video reading services and invests in R&D for next-generation capsule endoscopes and AI-based analytics engines.

CapsoVision's corporate office is in Saratoga, California, and its manufacturing is in Taiwan. The company sells its small bowel capsule system to gastroenterologists in clinics and hospitals in the U.S. and internationally. In the U.S., it sells directly to customers, while internationally, it sells directly and through qualified exclusive distributors. Its largest international markets are France, Germany, and Canada. In 2023, CapsoVision established a direct sales team in Germany. The majority of its revenue is generated from the United States.

CapsoVision's brand reputation has been positively influenced by FDA clearances for pediatric use and remote ingestion of the CapsoCam Plus® system, as well as ISO 27001 certification for its Information Security Management System. A stock dip in March 2026 following the Q4 2025 earnings report and a reduced price target could be perceived as a short-term negative event for investor confidence.

CapsoVision has a diverse ownership structure, with 41 institutional owners holding 1.54% to 1.64% of the shares. Insider ownership ranges from 17.58% to 29.7%, public companies hold about 6.91%, and the general public holds between 61.8% and 80.88%. Major institutional owners include BlackRock, Inc., Geode Capital Management, Llc, and Vanguard Group Inc. Major individual owners include Ching Hsing Shen, Eli Harari, and Hang Shen Ching.